take medidata, it's a provider that helps drug based companies. they had better than expected revenues that rose 27.2%. in response, the stock soared $16.42, or 22%, a massive move in single session and now they have given you a 30% gain. here is the company that is right at the confluence of cloud computing and drug development two smoking hot areas. can they keep going or will they run into a place where they do not have room to run, let's check in with the co-founder, chairman and ceo of medidata to learn more about this amazing quarter and what is in store for the company. thank you. right at the top you say there's a new sheriff at the fda. there's janet woodcock, and she is saying that tests have to be done a particular way. from the literature, you are the only company that is doing the tests the way the fda wants right now. >> jim, what janet woodcock is saying is that industry in conjunction with regulatory agencies have to change the way clinical trials are being done, what we help is our customers to do those trials in a very different